Photocure ASA (PHCUF)
6.18
-0.04
(-0.64%)
USD |
OTCM |
Jun 08, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 164.43M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | 24.85% |
| Valuation | |
| PE Ratio | 19.12 |
| PE Ratio (Forward) | |
| PS Ratio | 2.448 |
| Price to Book Value | 2.772 |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | 0.1633 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 76.03% |
Profile
| Photocure ASA engages in the development and commercialization of pharmaceutical products based on photodynamic technology. Its products include Metvix for nonmelanoma skin cancer, Hexvix/Cysview for better detection and management of bladder cancer, and Cevira which is a photodynamic drug-device combination product for non-surgical treatment of high-grade cervical dysplasia. The company operates through the Commercial Franchise and Development Portfolio segments. The Commercial Franchise segment includes the sale of Hexvix/Cysview in the U.S. and Europe and other sales from partners and other products. The Development Portfolio segment focuses on the development of pipeline products. The company was founded in 1997 and is headquartered in Oslo, Norway. |
| URL | http://ww.photocure.no |
| Investor Relations URL | N/A |
| HQ State/Province | Oslo |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Jul. 29, 2026 |
| Last Earnings Release | May. 07, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | May. 23, 2013 |
Profile
| Photocure ASA engages in the development and commercialization of pharmaceutical products based on photodynamic technology. Its products include Metvix for nonmelanoma skin cancer, Hexvix/Cysview for better detection and management of bladder cancer, and Cevira which is a photodynamic drug-device combination product for non-surgical treatment of high-grade cervical dysplasia. The company operates through the Commercial Franchise and Development Portfolio segments. The Commercial Franchise segment includes the sale of Hexvix/Cysview in the U.S. and Europe and other sales from partners and other products. The Development Portfolio segment focuses on the development of pipeline products. The company was founded in 1997 and is headquartered in Oslo, Norway. |
| URL | http://ww.photocure.no |
| Investor Relations URL | N/A |
| HQ State/Province | Oslo |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Jul. 29, 2026 |
| Last Earnings Release | May. 07, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | May. 23, 2013 |